BackX.T.L. Biopharmaceuticals Overview

X.T.L. Biopharmaceuticals Other Current Assets

Latest other current assets for XTLB: $22K.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$22000.00
77.55% YoYΔ $-76000.00 vs prior year quarter

Peer average

Loading

X.T.L. Biopharmaceuticals Other Current Assets History

Loading

X.T.L. Biopharmaceuticals vs. peers: Other Current Assets Comparison

Loading

X.T.L. Biopharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

X.T.L. Biopharmaceuticals (XTLB) FAQ

X.T.L. Biopharmaceuticals (XTLB) currently reports a other current assets of $22K as of December 2025. That compares with $98K in the prior-year period — down 77.6% year over year. Use the charts on this page to explore X.T.L. Biopharmaceuticals's other current assets history and peer comparisons.

X.T.L. Biopharmaceuticals's other current assets decreased from $98K to $22K — a 77.6% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

X.T.L. Biopharmaceuticals reported $22K in other current assets as of December 2025. That compares with $98K in the prior-year period — down 77.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $22K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for X.T.L. Biopharmaceuticals, and consider following XTLB for alerts when major investors trade the stock.

X.T.L. Biopharmaceuticals is classified in the Healthcare sector. On other current assets, it currently shows $22K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XTLB with unrelated industries.